RxDoctor Payments Data

Ann Macmurray

Family · Somers Point, NJNPI 1306125448

Payments from drug & device makers

$2,870in general payments, 2019–2025

Across 132 payments — averaging $21.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$547
  • Phathom Pharmaceuticals, Inc.$362
  • AstraZeneca$320
  • Lilly USA, LLC$312
  • Pfizer$296
  • Amgen$263
  • plus $770 from 13 others

What the payments were for

  • Food & beverage$2,82598%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,870 in reported general payments places this provider in the 90th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$170,109
Medicare patients
492
Services billed
1,940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate41$49,171
EliquisApixaban28$47,796
JardianceEmpagliflozin27$43,660
OzempicSemaglutide31$31,717
MyrbetriqMirabegron25$24,853
Icosapent Ethyl25$11,447
VascepaIcosapent Ethyl18$9,436
Atorvastatin Calcium615$6,683
Breo ElliptaFluticasone/Vilanterol12$5,449
SynthroidLevothyroxine Sodium56$4,121
Rosuvastatin Calcium277$3,579
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$3,539
Levothyroxine Sodium298$3,425
Fluticasone-SalmeterolFluticasone Propion/Salmeterol27$3,294
Losartan Potassium286$3,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$296$47,79628 claims
Boehringer IngelheimJardiance$50$43,66027 claims
Novo NordiskOzempic$547$31,71731 claims
GSKBreo Ellipta$15$5,44912 claims
AbbVieSynthroid$75$4,12156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,692 family providers in New Jersey.

Other family in Somers Point

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →